Monoclonals for patients hospitalised with COVID-19

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

“…Casirivimab/imdevimab was quickly shown to have negligible neutralising activity against Omicron ( Bruel et al, 2022 ) and its use quickly advised against in the UK and USA among other jurisdictions ( Department of Health Social Care, 2021 ). Nonetheless, newer synthetic antibody therapies such as tixagevimab-cilgavimab and sotrovimab, may provide therapeutic options against newer variants of SARS-CoV-2 and their utility continues to be investigated ( ACTIV-3-Therapeutics for Inpatients with COVID-19 (TICO) Study Group , Pogue and McCreary, 2022 ). We are yet to see whether the widespread adoption of early antiviral medications to prevent severe disease in high-risk groups, such as those with haematological malignancy, will also prevent the development of persistent infection.…”

COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study

“…To describe the clinical status of COVID-19 we used the NIAID ACTT-1 (National Institute of Allergy and Infectious Diseases Adaptive COVID-19 Treatment Trial-1) Clinical Status Ordinal Scale (16). Based on this score, we classified each patient with the infection into one of eight categories: (1) Not hospitalized, no limitations on activities; (2) Not hospitalized, limitation on activities, and/or requiring home oxygen; (3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (if hospitalization extended for infection-control purposes); (4) Hospitalized, not requiring supplemental oxygen; requiring ongoing medical care (COVID-19 related or otherwise); (5) Hospitalized, requiring supplemental oxygen; (6) Hospitalized, on noninvasive ventilation or high-flow oxygen devices; (7) Hospitalized, on invasive mechanical ventilation or ECMO; (8) Death (16).…”

“…Moreover, considering general population of patients with COVID-19, both monoclonal antibodies and antivirals have shown excellent results in reducing both hospitalization and the mortality rate, if administered early after symptoms onset (6)(7)(8). However, data regarding the impact of these drugs in SOT recipients with COVID-19 are scarce, because most studies excluded solid organ transplants (9)(10)(11).…”